Drug Profile
Ipafricept - Bayer HealthCare Pharmaceuticals/OncoMed Pharmaceuticals
Alternative Names: Fzd8-Fc; Ipafricept; OMP 54F28Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals; OncoMed Pharmaceuticals
- Class Antineoplastics; Disulfides; Immunoglobulin Fc fragments; Immunoglobulin fusion proteins; Proteins; Recombinant fusion proteins
- Mechanism of Action Frizzled 8 receptor modulators; Wnt protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Liver cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Highest Development Phases
- Suspended Liver cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Most Recent Events
- 24 Apr 2019 OncoMed Pharmaceuticals has been acquired by Mereo BioPharma
- 01 Dec 2017 OncoMed Pharmaceuticals completes a phase I trial for Ovarian cancer (Combination therapy, Recurrent, Second-line therapy or greater, In adults, In the elderly) in USA (IV) (NCT02092363)
- 01 Jul 2017 OncoMed Pharmaceuticals completes a phase I trial for liver cancer (Combination therapy, First-line therapy, Late-stage disease, Metastatic disease) in USA (IV) (NCT02069145)